Evidence map›Paper›PMID 40355675›Full record

ArticleHIV medicine2025

Dual cross-sectional and longitudinal perspective on the continuum of HIV care to disentangle natural epidemic evolution from real progress, Belgium 2014-2022.

D Van Beckhoven, B Serrien, R Demeester, J Van Praet, P Messiaen, G Darcis, S Henrard, P De Munter, A Libois, J Deblonde

Abstract read
In one paragraph

Article in HIV medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Observational
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

D Van BeckhovenDepartment of Epidemiology and Public Health, Sciensano, Brussels, Belgium.ORCID https://orcid.org/0000-0003-0821-2756
B SerrienDepartment of Epidemiology and Public Health, Sciensano, Brussels, Belgium.ORCID https://orcid.org/0000-0001-5542-997X
R DemeesterDepartment of Internal Medicine and Infectious Diseases, University Hospital of Charleroi, Lodelinsart, Belgium.ORCID https://orcid.org/0000-0002-2979-4321
J Van PraetDepartment of Nephrology and Infectious Diseases, AZ Sint-Jan Brugge, Brugge, Belgium.ORCID https://orcid.org/0000-0002-7125-7001
P MessiaenDepartment of Infectious Diseases and Immunity, Jessa Hospital, Hasselt, Belgium.ORCID https://orcid.org/0000-0001-9619-1291
G DarcisDepartment of Infectious Diseases, University Hospital of Liège, Liège, Belgium.ORCID https://orcid.org/0000-0001-8192-1351
S HenrardHIV Reference Centre and Internal Medicine, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.ORCID https://orcid.org/0000-0001-9486-5547
P De MunterDepartment of General Internal Medicine, UZ Leuven, Leuven, Belgium.ORCID https://orcid.org/0000-0002-5944-3530
A LiboisDepartment of Infectious Diseases, CHU Saint-Pierre, Université Libre de Bruxelles, Brussels, Belgium.ORCID https://orcid.org/0000-0002-6078-878X
J DeblondeDepartment of Epidemiology and Public Health, Sciensano, Brussels, Belgium.ORCID https://orcid.org/0000-0002-8989-0091

Funding

National Institute for Health and Disability Insurance
6 · The paper itself

Abstract

introductionThis study provides a comprehensive overview of HIV care by combining cross-sectional and longitudinal continuum of care (CoC) analyses.

methodsUsing national surveillance data 2014-2022, a five-stage cross-sectional CoC was calculated among people living with HIV (incl. undiagnosed): diagnosed, linked to care, retained in care, on antiretroviral therapy (ART) and virally suppressed. For the longitudinal CoC, cumulative incidences (CI) were calculated for each transition.

resultsThe study included 26 191 people living with HIV. By the end of 2022, an estimated 18 302 persons were living with HIV in Belgium. Of these, 92.1% were diagnosed, 90.9% linked to care, 89.2% retained in care, 87.9% on ART and 85.6% virally suppressed. One-year post-infection diagnosis rates were 38% (2014-2016), 33% (2017-2019) and 31% (2020-2022), with differences disappearing after correction for immigration timing. Time from diagnosis to care entry remained stable at 82% within 3 months. Time to ART initiation and to viral load suppression reduced substantially, with 3-month CIs rising from 69% and 71%, respectively (2014-2016), to 91% and 77% (2020-2022). Transitions between all stages of care were the fastest among Belgian men who have sex with men. People who inject drugs had the lowest CI for care entry and viral suppression. Cumulative incidences of ART initiation increased substantially for all key populations, exceeding 90% within 3 months in 2020-2022, except for non-Belgian heterosexuals (87%).

conclusionA steady improvement in the CoC places Belgium close to the joint united nations programme on HIV/AIDS 95-95-95 targets, although populations like people who inject drugs and migrants still face significant barriers to care. Timely diagnosis by supporting existing and innovative testing strategies should be prioritized.

Indexed as

Continuity of Patient CareHIV InfectionsAdultAnti-HIV AgentsBelgiumCross-Sectional StudiesEpidemicsFemaleHumansIncidenceLongitudinal StudiesMaleMiddle AgedViral LoadYoung AdultAnti-HIV AgentsBelgiumcare cascadecontinuum of carecross‐sectionalHIVkey populationlongitudinal

Identifiers

PMID40355675
PMCPMC12210343

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.